Among the core assets that Gilead (Nasdaq: GILD) acquired from Myogen in 2006 for $2.5B was Letairis® (ambrisentan), for the treatment of pulmonary arterial hypertension (PAH), which was then approved by the FDA in mid 2007. After about a quarter in the market Gilead has initiated a Phase IV, randomized, double-blind, placebo-controlled study evaluating Letairis® [...]

• 386http://clsdf.com/2008/05/off-to-phase-iv-for-letairis%c2%ae-and-the-market-for-volibris%c2%ae/Off+to+Phase+IV+for+Letairis%C2%AE+and+the+Market+for+Volibris%C2%AE2008-05-02+15%3A01%3A00admin

Congratulations to Michael Bristow, M.D., Ph.D., the S. Gilbert Blount Professor of Medicine at University of Colorado, Head of Cardiology, Co-director of the University of Colorado Cardiovascular Institute, co-founder of Myogen (acquired by Gilead (NASDAQ: GILD), founder of ARCA Discovery and now add to that list winner of the Pharmaceutical Research and Manufacturers of America [...]

• 333http://clsdf.com/2008/02/michael-bristow-m-d-ph-d-wins-2008-phrma-award/Michael+Bristow%2C+M.D.%2C+Ph.D.+Wins+2008+PhRMA+Award2008-02-29+14%3A28%3A00admin

Gilead (NASDAQ: GILD) announced total revenues for 3Q07 of $1.06B, up 41% percent compared to total revenues of $748.7MM for 3Q06, along with record product sales of $962MM, up 44% over 3Q06! An amazing 90-day run, but what I am most interested in is how is Letaris® (ambrisentan) faring? Now don’t quote me here because [...]

• 241http://clsdf.com/2007/10/gilead-racks-up-quarterly-record/Gilead+Racks+Up+Quarterly+Record2007-10-20+13%3A45%3A00admin

You can hear the champagne corks popping from Westminster, CO to Foster City, CA as the FDA late Friday approved Gilead‘s (Myogen) Letairis® (ambrisentan) for the treatment of pulmonary arterial hypertension (PAH). There are up to an estimated 90,000 people in the US suffering from PAH, a disease where blood pressure is raised due to [...]

• 187http://clsdf.com/2007/06/fda-approval-for-letairis-ambrisentan/FDA+Approval+for+Letairis+%28Ambrisentan%29%21%21%212007-06-19+17%3A51%3A00admin

Happily tracking the progress of Gilead Sciences, Inc. (NASDAQ: GILD) Ambrisentan asset; for the treatment of pulmonary arterial hypertension. Gilead’s recent announcement that the FDA has accepted for filing and granted a priority review for the NDA is exciting news for the Colorado bio-scape. This approval may result in an accelerated review with an expectation [...]

• 154http://clsdf.com/2007/02/ambrisentan-moving-closer-to-approval/Ambrisentan+Moving+Closer+to+Approval2007-02-17+03%3A54%3A00admin